Category Press Releases

Oticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS

Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…

Read MoreOticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS

IDT and Hamilton Partner to Automate NGS and Boost Biomarker Discovery

IDT and Hamilton Partner to Automate NGS Workflows, Accelerating Biomarker and Genomic Discovery Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a new strategic partnership with precision laboratory automation pioneer Hamilton (Hamilton Company and Hamilton Bonaduz…

Read MoreIDT and Hamilton Partner to Automate NGS and Boost Biomarker Discovery
Pulse Biosciences

Pulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025

Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of its novel nPulse™ technology based on Nanosecond Pulsed Field Ablation™…

Read MorePulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025
Prilenia

Prilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress

Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…

Read MorePrilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress

Eikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD

Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative and cardiorenal diseases, has announced the advance online publication of…

Read MoreEikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD

Laurus Labs Invests in Aarvik Therapeutics’ Series Seed 2 Funding Round

Aarvik Therapeutics Secures Strategic Investment from Laurus Labs in Series Seed 2 Financing Round Aarvik Therapeutics, a pioneering biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, today announced a strategic investment by Laurus Labs, India, as…

Read MoreLaurus Labs Invests in Aarvik Therapeutics’ Series Seed 2 Funding Round
Celltrion

Celltrion Shares Positive Real-World Data on IV-to-SC Infliximab Switch at UEG Week 2025

Celltrion Showcases Real-World Evidence Supporting Switch from IV to Subcutaneous Infliximab at UEG Week 2025 Celltrion, Inc., a global leader in biopharmaceutical innovation, today highlighted compelling real-world evidence supporting the use of subcutaneous (SC) infliximab for patients with inflammatory bowel…

Read MoreCelltrion Shares Positive Real-World Data on IV-to-SC Infliximab Switch at UEG Week 2025

KalVista Showcases EKTERLY® Data Demonstrating Transformative Potential in HAE Treatment

KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…

Read MoreKalVista Showcases EKTERLY® Data Demonstrating Transformative Potential in HAE Treatment

Sonoma Biotherapeutics Co-Founder Fred Ramsdell Wins 2025 Nobel Prize in Medicine

Sonoma Biotherapeutics Co-Founder Fred Ramsdell Awarded 2025 Nobel Prize in Physiology or Medicine for Pioneering FOXP3 Discovery and Advancing Treg Immunotherapy Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune…

Read MoreSonoma Biotherapeutics Co-Founder Fred Ramsdell Wins 2025 Nobel Prize in Medicine

Ignota Labs Strengthens Portfolio with Acquisition of Kronos’s Clinical-Stage Pipeline

Ignota Labs Strengthens Clinical Portfolio Through Acquisition of Kronos’s Development-Stage Assets Ignota Labs, an emerging pioneer in artificial intelligence–driven drug redevelopment, has announced the strategic acquisition of Kronos’s former clinical assets—istisociclib, a cyclin-dependent kinase 9 (CDK9) inhibitor, and entospletinib and…

Read MoreIgnota Labs Strengthens Portfolio with Acquisition of Kronos’s Clinical-Stage Pipeline